View More Recent Stories
-
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
-
Roth/MKM Reiterates Buy Rating on Cardiol Therapeutics (CRDL)
-
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
-
Cardiol Therapeutics (CRDL) Announces Completion of the MAvERIC Phase II Study
-
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024
-
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
-
Roth/MKM Starts Cardiol Therapeutics (CRDL) at Buy
-
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
-
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

